Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)
NCT ID: NCT05550207
Last Updated: 2025-12-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
100 participants
INTERVENTIONAL
2022-08-31
2024-11-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Initiating Early Control of Migraine Pain and Associated Symptoms
NCT04163185
Maximizing Outcomes in Treating Acute Migraine
NCT03896009
Multimechanistic Treatment Over Time of Migraine Symptoms (MOVEMENT)
NCT04068051
A Study of the Effectiveness and Safety of Almotriptan Versus Placebo in the Treatment of Migraine Headache
NCT00210509
Potential Impact (Benefit) of Preventative Treatment With Topamax on the Effectiveness of Axert in the Acute Treatment of Migraine
NCT00210496
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AXS-07 (meloxicam-rizatriptan)
Up to 8 weeks
AXS-07 (meloxicam-rizatriptan)
AXS-07 tablets, taken orally for the acute treatment of migraine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AXS-07 (meloxicam-rizatriptan)
AXS-07 tablets, taken orally for the acute treatment of migraine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has experienced an inadequate response to oral CGRP inhibitors for the acute treatment of migraine
Exclusion Criteria
* Has previously received any investigational drug or device or investigational therapy within 30 days before Screening
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Axsome Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Research Site
Colton, California, United States
Clinical Research Site
Fullerton, California, United States
Clinical Research Site
La Jolla, California, United States
Clinical Research Site
Los Angeles, California, United States
Clinical Research Site
Sherman Oaks, California, United States
Clinical Research Site
Stamford, Connecticut, United States
Clinical Research Site
DeLand, Florida, United States
Clinical Research Site
Hallandale, Florida, United States
Clinical Research Site
Hollywood, Florida, United States
Clinical Research Site
Miami, Florida, United States
Clinical Research Site
Ormond Beach, Florida, United States
Clinical Research Site
Oviedo, Florida, United States
Clinical Research Site
Pensacola, Florida, United States
Clinical Research Site
Winter Park, Florida, United States
Clinical Research Site
Stockbridge, Georgia, United States
Clinical Research Site
Avon, Indiana, United States
Clinical Research Site
Boston, Massachusetts, United States
Clinical Research Site
North Dartmouth, Massachusetts, United States
Clinical Research Site
Las Vegas, Nevada, United States
Clinical Research Site
Albuquerque, New Mexico, United States
Clinical Research Site
The Bronx, New York, United States
Clinical Research Site
Williamsville, New York, United States
Clinical Research Site
Philadelphia, Pennsylvania, United States
Clinical Research Site
Charleston, South Carolina, United States
Clinical Research Site
Knoxville, Tennessee, United States
Clinical Research Site
Nashville, Tennessee, United States
Clinical Research Site
Cypress, Texas, United States
Clinical Research Site
Sugar Land, Texas, United States
Clinical Research Site
Salt Lake City, Utah, United States
Clinical Research Site
Charlottesville, Virginia, United States
Clinical Research Site
McLean, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Axsome Therapeutics Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AXS-07-304
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.